Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies
详细信息 查看全文
- 作者：Shujing Wang ; Huiqin Liu ; Xinyi Zhang ; Feng Qian
- 关键词：mucosal vaccine ; protein antigen ; adjuvant ; immunostimulant ; vaccine delivery system
- 刊名：Protein & Cell
- 出版年：2015
- 出版时间：July 2015
- 年：2015
- 卷：6
- 期：7
- 页码：480-503
- 全文大小：619 KB
- 参考文献：Abusugra I, Morein B (1999) Iscom is an efficient mucosal delivery system for Mycoplasma mycoides subsp. mycoides (MmmSC) antigens inducing high mucosal and systemic antibody responses. FEMS Immunol Med Microbiol 23:5鈥?2PubMed
Ali R, Kumar S, Naqvi RA, Sheikh IA, Rao DN (2013) Multiple antigen peptide consisting of B- and T-cell epitopes of F1 antigen of Y. pestis showed enhanced humoral and mucosal immune response in different strains of mice. Int Immunopharmacol 15:97鈥?05PubMed
Almeida AJ, Alpar HO (1996) Nasal delivery of vaccines. J Drug Target 3:455鈥?67PubMed
Alpar HO, Eyles JE, Williamson ED, Somavarapu S (2001) Intranasal vaccination against plague, tetanus and diphtheria. Adv Drug Deliv Rev 51:173鈥?01PubMed
Bachmann MF, Jennings GT (2010) Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 10:787鈥?96PubMed
Bal SM, Slutter B, Verheul R, Bouwstra JA, Jiskoot W (2012) Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: adjuvant- and site-dependent immunogenicity in mice. Eur J Pharm Sci 45:475鈥?81PubMed
Ball JM, Hardy ME, Atmar RL, Conner ME, Estes MK (1998) Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice. J Virol 72:1345鈥?353PubMed Central PubMed
Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245鈥?52PubMed
Barhate G, Gautam M, Gairola S, Jadhav S, Pokharkar V (2013) Quillaja saponaria extract as mucosal adjuvant with chitosan functionalized gold nanoparticles for mucosal vaccine delivery: stability and immunoefficiency studies. Int J Pharm 441:636鈥?42PubMed
Baudner BC, O鈥橦agan DT (2010) Bioadhesive delivery systems for mucosal vaccine delivery. J Drug Target 18:752鈥?70PubMed
Belyakov IM, Moss B, Strober W, Berzofsky JA (1999) Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc Natl Acad Sci USA 96:4512鈥?517PubMed Central PubMed
Borges O, Tavares J, de Sousa A, Borchard G, Junginger HE, Cordeiro-da-Silva A (2007) Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles. Eur J Pharm Sci 32:278鈥?90PubMed
Borges O, Cordeiro-da-Silva A, Tavares J, Santarem N, de Sousa A, Borchard G, Junginger HE (2008) Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles. Eur J Pharm Biopharm 69:405鈥?16PubMed
Boyaka PN, Marinaro M, Jackson RJ, Menon S, Kiyono H, Jirillo E, McGhee JR (1999) IL-12 is an effective adjuvant for induction of mucosal immunity. J Immunol 162:122鈥?28PubMed
Brandhonneur N, Loizel C, Chevanne F, Wakeley P, Jestin A, Le Potier MF, Le Corre P (2009) Mucosal or systemic administration of rE2 glycoprotein antigen loaded PLGA microspheres. Int J Pharm 373:16鈥?3PubMed
Brunner R, Jensen-Jarolim E, Pali-Scholl I (2010) The ABC of clinical and experimental adjuvants鈥揳 brief overview. Immunol Lett 128:29鈥?5PubMed Central PubMed
Buffa V, Klein K, Fischetti L, Shattock RJ (2012) Evaluation of TLR agonists as potential mucosal adjuvants for HIV gp140 and tetanus toxoid in mice. Plos One 7:e50529PubMed Central PubMed
Burdette DL, Monroe KM, Sotelo-Troha K, Iwig JS, Eckert B, Hyodo M, Hayakawa Y, Vance RE (2011) STING is a direct innate immune sensor of cyclic di-GMP. Nature 478:515鈥?18PubMed Central PubMed
Caley IJ, Betts MR, Irlbeck DM, Davis NL, Swanstrom R, Frelinger JA, Johnston RE (1997) Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J Virol 71:3031鈥?038PubMed Central PubMed
Carcaboso AM, Hernandez RM, Igartua M, Gascon AR, Rosas JE, Patarroyo ME, Pedraz JL (2003) Immune response after oral administration of the encapsulated malaria synthetic peptide SPf66. Int J Pharm 260:273鈥?82PubMed
Challacombe SJ, Rahman D, Jeffery H, Davis SS, O鈥橦agan DT (1992) Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunology 76:164鈥?68PubMed Central PubMed
Chen YS, Hung YC, Lin WH, Huang GS (2010) Assessment of gold nanoparticles as a size-dependent vaccine carrier for enhancing the antibody response against synthetic foot-and-mouth disease virus peptide. Nanotechnology 21:195101PubMed
Chen J, Li Z, Huang H, Yang Y, Ding Q, Mai J, Guo W, Xu Y (2011) Improved antigen cross-presentation by polyethyleneimine-based nanoparticles. Int J Nanomed 6:77鈥?4
Clark MA, Blair H, Liang L, Brey RN, Brayden D, Hirst BH (2001) Targeting polymerised liposome vaccine carriers to intestinal M cells. Vaccine 20:208鈥?17PubMed
Cortesi R, Ravani L, Rinaldi F, Marconi P, Drechsler M, Manservigi M, Argnani R, Menegatti E, Esposito E, Manservigi R (2013) Intranasal immunization in mice with non-ionic surfactants vesicles containing HSV immunogens: a preliminary study as possible vaccine against genital herpes. Int J Pharm 440:229鈥?37PubMed
Courtney AN, Nehete PN, Nehete BR, Thapa P, Zhou DP, Sastry KJ (2009) Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens. Vaccine 27:3335鈥?341PubMed
Cox E, Verdonck F, Vanrompay D, Goddeeris B (2006) Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa. Vet Res 37:511鈥?39PubMed
Cruz LJ, Tacken PJ, Rueda F, Domingo JC, Albericio F, Figdor CG (2012) Targeting nanoparticles to dendritic cells for immunotherapy. Methods Enzymol 509:143鈥?63PubMed
Dawidczyk CM, Kim C, Park JH, Russell LM, Lee KH, Pomper MG, Searson PC (2014) State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. J Control Release 187:133鈥?44PubMed
De Filette M, Fiers W, Martens W, Birkett A, Ramne A, Lowenadler B, Lycke N, Jou WM, Saelens X (2006) Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 24:6597鈥?601PubMed
De Gregorio E, Rappuoli R (2014) From empiricism to rational design: a personal perspective of the evolution of vaccine development. Nat Rev Immunol 14:505鈥?14PubMed
Degim IT, Celebi N (2007) Controlled delivery of peptides and proteins. Curr Pharm Des 13:99鈥?17PubMed
Demento SL, Siefert AL, Bandyopadhyay A, Sharp FA, Fahmy TM (2011) Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines. Trends Biotechnol 29:294鈥?06PubMed
Deschuyteneer M, Elouahabi A, Plainchamp D, Plisnier M, Soete D, Corazza Y, Lockman L, Giannini S, Deschamps M (2010) Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix (TM), the AS04-adjuvanted HPV-16 and-18 cervical cancer vaccine. Hum Vaccines 6:407鈥?19
Devriendt B, De Geest BG, Goddeeris BM, Cox E (2012) Crossing the barrier: targeting epithelial receptors for enhanced oral vaccine delivery. J Control Release 160:431鈥?39PubMed
Dormitzer PR, Grandi G, Rappuoli R (2012) Structural vaccinology starts to deliver. Nat Rev Microbiol 10:807鈥?13PubMed
Du L, Zhao G, He Y, Guo Y, Zheng BJ, Jiang S, Zhou Y (2007) Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine 25:2832鈥?838PubMed
Du L, Kou Z, Ma C, Tao X, Wang L, Zhao G, Chen Y, Yu F, Tseng CT, Zhou Y et al (2013a) A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS One 8:e81587PubMed Central PubMed
Du L, Zhao G, Kou Z, Ma C, Sun S, Poon VK, Lu L, Wang L, Debnath AK, Zheng BJ et al (2013b) Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol 87:9939鈥?942PubMed Central PubMed
Eastcott JW, Holmberg CJ, Dewhirst FE, Esch TR, Smith DJ, Taubman MA (2001) Oligonucleotide containing CpG motifs enhances immune response to mucosally or systemically administered tetanus toxoid. Vaccine 19:1636鈥?642PubMed
Ebensen T, Schulze K, Riese P, Morr M, Guzman CA (2007) The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant. Clin Vaccine Immunol 14:952鈥?58PubMed Central PubMed
Ebensen T, Libanova R, Schulze K, Yevsa T, Morr M, Guzman CA (2011) Bis-(3鈥?5鈥?-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant. Vaccine 29:5210鈥?220PubMed
Elamanchili P, Lutsiak CM, Hamdy S, Diwan M, Samuel J (2007) 鈥淧athogen-mimicking鈥?nanoparticles for vaccine delivery to dendritic cells. J Immunother 30:378鈥?95PubMed
Ellis JA, West KH, Waldner C, Rhodes C (2005) Efficacy of a saponin-adjuvanted inactivated respiratory syncytial virus vaccine in calves. Can Vet J 46:155鈥?62PubMed Central PubMed
Eyles JE, Sharp GJ, Williamson ED, Spiers ID, Alpar HO (1998) Intra nasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse. Vaccine 16:698鈥?07PubMed
Eyles JE, Williamson ED, Spiers ID, Stagg AJ, Jones SM, Alpar HO (2000) Generation of protective immune responses to plague by mucosal administration of microsphere coencapsulated recombinant subunits. J Control Release 63:191鈥?00PubMed
Florindo HF, Pandit S, Lacerda L, Goncalves LMD, Alpar HO, Almeida AJ (2009) The enhancement of the immune response against S. equi antigens through the intranasal administration of poly-epsilon-caprolactone-based nanoparticles. Biomaterials 30:879鈥?91PubMed
Fujita Y, Taguchi H (2011) Current status of multiple antigen-presenting peptide vaccine systems: application of organic and inorganic nanoparticles. Chem Cent J 5:48PubMed Central PubMed
Garcia A, De Sanctis JB (2014) An overview of adjuvant formulations and delivery systems. APMIS 122:257鈥?67PubMed
Garcia-Fuentes M, Alonso MJ (2012) Chitosan-based drug nanocarriers: where do we stand? J Control Release 161:496鈥?04PubMed
Garinot M, Fievez V, Pourcelle V, Stoffelbach F, des Rieux A, Plapied L, Theate I, Freichels H, Jerome C, Marchand-Brynaert J et al (2007) PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J Control Release 120:195鈥?04PubMed
Gherardi MM, Esteban M (2005) Recombinant poxviruses as mucosal vaccine vectors. J Gen Virol 86:2925鈥?936PubMed
Gosselin EJ, Bitsaktsis C, Li Y, Iglesias BV (2009) Fc receptor-targeted mucosal vaccination as a novel strategy for the generation of enhanced immunity against mucosal and non-mucosal pathogens. Arch Immunol Ther Exp (Warsz) 57:311鈥?23
Graham RL, Donaldson EF, Baric RS (2013) A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol 11:836鈥?48PubMed
Grgacic EV, Anderson DA (2006) Virus-like particles: passport to immune recognition. Methods 40:60鈥?5PubMed
Guerrero RA, Ball JM, Krater SS, Pacheco SE, Clements JD, Estes MK (2001) Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J Virol 75:9713鈥?722PubMed Central PubMed
Gupta PN, Khatri K, Goyal AK, Mishra N, Vyas SP (2007) M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B. J Drug Target 15:701鈥?13PubMed
Hamdy S, Haddadi A, Hung RW, Lavasanifar A (2011) Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv Drug Deliv Rev 63:943鈥?55PubMed
Hiroi T, Goto H, Someya K, Yanagita M, Honda M, Yamanaka N, Kiyono H (2001) HIV mucosal vaccine: nasal immunization with rBCG-V3J1 induces a long term V3J1 peptide-specific neutralizing immunity in Th1- and Th2-deficient conditions. J Immunol 167:5862鈥?867PubMed
Holmgren J, Czerkinsky C (2005) Mucosal immunity and vaccines. Nat Med 11:S45鈥?3PubMed
Hu KF, Elvander M, Merza M, Akerblom L, Brandenburg A, Morein B (1998) The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses. Clin Exp Immunol 113:235鈥?43PubMed Central PubMed
Hu KF, Lovgren-Bengtsson K, Morein B (2001) Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv Drug Deliv Rev 51:149鈥?59PubMed
Huang X, Lu B, Yu W, Fang Q, Liu L, Zhuang K, Shen T, Wang H, Tian P, Zhang L et al (2009) A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination. PLoS One 4:e4180PubMed Central PubMed
Ibanez LI, Roose K, De Filette M, Schotsaert M, De Sloovere J, Roels S, Pollard C, Schepens B, Grooten J, Fiers W et al (2013) M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A. PLoS One 8:e59081PubMed Central PubMed
Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, Tamura S, Takahashi H, Sawa H, Chiba J, Kurata T et al (2005) Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol 79:2910鈥?919PubMed Central PubMed
Ichinohe T, Watanabe I, Tao E, Ito S, Kawaguchi A, Tamura S, Takahashi H, Sawa H, Moriyama M, Chiba J et al (2006) Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant. J Med Virol 78:954鈥?63PubMed
Igartua M, Hernandez RM, Esquisabel A, Gascon AR, Calvo MB, Pedraz JL (1998) Enhanced immune response after subcutaneous and oral immunization with biodegradable PLGA microspheres. J Control Release 56:63鈥?3PubMed
Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS (2001) Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliver Rev 51:81鈥?6
Ishii M, Kojima N (2010) Mucosal adjuvant activity of oligomannose-coated liposomes for nasal immunization. Glycoconj J 27:115鈥?23PubMed
Ishikawa H, Ma Z, Barber GN (2009) STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 461:788鈥?92PubMed
Jaganathan KS, Vyas SP (2006) Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. Vaccine 24:4201鈥?211PubMed
Jaganathan KS, Rao YU, Singh P, Prabakaran D, Gupta S, Jain A, Vyas SP (2005) Development of a single dose tetanus toxoid formulation based on polymeric microspheres: a comparative study of poly(d , l -lactic-co-glycolic acid) versus chitosan microspheres. Int J Pharm 294:23鈥?2PubMed
Jain AK, Goyal AK, Mishra N, Vaidya B, Mangal S, Vyas SP (2010) PEG-PLA-PEG block copolymeric nanoparticles for oral immunization against hepatitis B. Int J Pharm 387:253鈥?62PubMed
Jain S, Harde H, Indulkar A, Agrawal AK (2014) Improved stability and immunological potential of tetanus toxoid containing surface engineered bilosomes following oral administration. Nanomedicine 10:431鈥?40PubMed
Jariyapong P, Xing L, van Houten NE, Li TC, Weerachatyanukul W, Hsieh B, Moscoso CG, Chen CC, Niikura M, Cheng RH (2013) Chimeric hepatitis E virus-like particle as a carrier for oral-delivery. Vaccine 31:417鈥?24PubMed
Jiang T, Singh B, Li HS, Kim YK, Kang SK, Nah JW, Choi YJ, Cho CS (2014) Targeted oral delivery of BmpB vaccine using porous PLGA microparticles coated with M cell homing peptide-coupled chitosan. Biomaterials 35:2365鈥?373PubMed
Kanekiyo M, Wei CJ, Yassine HM, McTamney PM, Boyington JC, Whittle JRR, Rao SS, Kong WP, Wang LS, Nabel GJ (2013) Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499:102鈥?06PubMed
Kang SM, Guo L, Yao Q, Skountzou I, Compans RW (2004) Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens. J Virol 78:9624鈥?632PubMed Central PubMed
Kanzler H, Barrat FJ, Hessel EM, Coffman RL (2007) Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 13:552鈥?59PubMed
Kavanagh OV, Earley B, Murray M, Foster CJ, Adair BM (2003) Antigen-specific IgA and IgG responses in calves inoculated intranasally with ovalbumin encapsulated in poly(dl -lactide-co-glycolide) microspheres. Vaccine 21:4472鈥?480PubMed
Kavanagh OV, Adair BM, Welsh MD, Earley B (2013) Local and systemic immune responses in mice to intranasal delivery of peptides representing bovine respiratory syncytial virus epitopes encapsulated in poly (dl -lactide-co-glycolide) microparticles. Res Vet Sci 94:809鈥?12PubMed
Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, Ueno H, Nakagawa R, Sato H, Kondo E et al (1997) CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278:1626鈥?629PubMed
Kayamuro H, Yoshioka Y, Abe Y, Katayama K, Yoshida T, Yamashita K, Yoshikawa T, Hiroi T, Itoh N, Kawai Y et al (2009) TNF superfamily member, TL1A, is a potential mucosal vaccine adjuvant. Biochem Biophys Res Commun 384:296鈥?00PubMed
Kayamuro H, Yoshioka Y, Abe Y, Arita S, Katayama K, Nomura T, Yoshikawa T, Kubota-Koketsu R, Ikuta K, Okamoto S et al (2010) Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus. J Virol 84:12703鈥?2712PubMed Central PubMed
Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE, Shen F, Eaton SM, Gaffen SL, Swain SL et al (2007) IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8:369鈥?77PubMed
Khader SA, Gaffen SL, Kolls JK (2009) Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol 2:403鈥?11PubMed Central PubMed
Kim SH, Lee KY, Kim J, Park SM, Park BK, Jang YS (2006) Identification of a peptide enhancing mucosal and systemic immune responses against EGFP after oral administration in mice. Mol Cells 21:244鈥?50PubMed
Kim SH, Seo KW, Kim J, Lee KY, Jang YS (2010) The M cell-targeting ligand promotes antigen delivery and induces antigen-specific immune responses in mucosal vaccination. J Immunol 185:5787鈥?795PubMed
Klinman DM, Currie D, Gursel I, Verthelyi D (2004) Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev 199:201鈥?16PubMed
Klippstein R, Pozo D (2010) Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Nanomedicine 6:523鈥?29PubMed
Kobayashi T, Fukushima K, Sannan T, Saito N, Takiguchi Y, Sato Y, Hasegawa H, Ishikawa K (2013) Evaluation of the effectiveness and safety of chitosan derivatives as adjuvants for intranasal vaccines. Viral Immunol 26:133鈥?42PubMed
Kong IG, Sato A, Yuki Y, Nochi T, Takahashi H, Sawada S, Mejima M, Kurokawa S, Okada K, Sato S et al (2013) Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae. Infect Immun 81:1625鈥?634PubMed Central PubMed
Koping-Hoggard M, Sanchez A, Alonso MJ (2005) Nanoparticles as carriers for nasal vaccine delivery. Expert Rev Vaccines 4:185鈥?96PubMed
Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546鈥?49PubMed
Krugman S (1982) The newly licensed hepatitis B vaccine. Characteristics and indications for use. JAMA 247:2012鈥?015PubMed
Lamphear BJ, Jilka JM, Kesl L, Welter M, Howard JA, Streatfield SJ (2004) A corn-based delivery system for animal vaccines: an oral transmissible gastroenteritis virus vaccine boosts lactogenic immunity in swine. Vaccine 22:2420鈥?424PubMed
Lawson LB, Norton EB, Clements JD (2011) Defending the mucosa: adjuvant and carrier formulations for mucosal immunity. Curr Opin Immunol 23:414鈥?20PubMed
Lema D, Garcia A, De Sanctis JB (2014) HIV vaccines: a brief overview. Scand J Immunol 80:1鈥?1PubMed
Lemesre JL, Holzmuller P, Goncalves RB, Bourdoiseau G, Hugnet C, Cavaleyra M, Papierok G (2007) Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial. Vaccine 25:4223鈥?234PubMed
Lewis DJ, Huo Z, Barnett S, Kromann I, Giemza R, Galiza E, Woodrow M, Thierry-Carstensen B, Andersen P, Novicki D et al (2009) Transient facial nerve paralysis (Bell鈥檚 palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 4:e6999PubMed Central PubMed
Lewis JS, Zaveri TD, Crooks CP 2nd, Keselowsky BG (2012) Microparticle surface modifications targeting dendritic cells for non-activating applications. Biomaterials 33:7221鈥?232PubMed Central PubMed
Li T, Takeda N, Miyamura T (2001) Oral administration of hepatitis E virus-like particles induces a systemic and mucosal immune response in mice. Vaccine 19:3476鈥?484PubMed
Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC et al (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426:450鈥?54PubMed
Li K, Chen D, Zhao X, Hu H, Yang C, Pang D (2011a) Preparation and investigation of Ulex europaeus agglutinin I-conjugated liposomes as potential oral vaccine carriers. Arch Pharm Res 34:1899鈥?907PubMed
Li K, Zhao X, Xu S, Pang D, Yang C, Chen D (2011b) Application of Ulex europaeus agglutinin I-modified liposomes for oral vaccine: Ex Vivo bioadhesion and in Vivo immunity. Chem Pharm Bull (Tokyo) 59:618鈥?23
Libanova R, Ebensen T, Schulze K, Bruhn D, Norder M, Yevsa T, Morr M, Guzman CA (2010) The member of the cyclic di-nucleotide family bis-(3鈥?5鈥?-cyclic dimeric inosine monophosphate exerts potent activity as mucosal adjuvant (vol 28, pg 2249, 2010). Vaccine 28:3625鈥?625
Liu X, Chen DW, Xie LP, Zhang RQ (2003) Oral colon-specific drug delivery for bee venom peptide: development of a coated calcium alginate gel beads-entrapped liposome. J Control Release 93:293鈥?00
Liu L, Wei Q, Alvarez X, Wang H, Du Y, Zhu H, Jiang H, Zhou J, Lam P, Zhang L et al (2011) Epithelial cells lining salivary gland ducts are early target cells of severe acute respiratory syndrome coronavirus infection in the upper respiratory tracts of rhesus macaques. J Virol 85:4025鈥?030PubMed Central PubMed
Lu G, Hu Y, Wang Q, Qi J, Gao F, Li Y, Zhang Y, Zhang W, Yuan Y, Bao J et al (2013) Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 500:227鈥?31PubMed
Lycke N (2012) Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol 12:592鈥?05PubMed
Ma C, Li Y, Wang L, Zhao G, Tao X, Tseng CT, Zhou Y, Du L, Jiang S (2014a) Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. Vaccine 32:2100鈥?108PubMed Central PubMed
Ma T, Wang L, Yang T, Ma G, Wang S (2014b) M-cell targeted polymeric lipid nanoparticles containing a toll-like receptor agonist to boost oral immunity. Int J Pharm 473:296鈥?03PubMed
Maisonneuve C, Bertholet S, Philpott DJ, De Gregorio E (2014) Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants. Proc Natl Acad Sci USA 111:12294鈥?2299PubMed Central PubMed
Malik B, Goyal AK, Markandeywar TS, Rath G, Zakir F, Vyas SP (2012) Microfold-cell targeted surface engineered polymeric nanoparticles for oral immunization. J Drug Target 20:76鈥?4PubMed
Maloy KJ, Donachie AM, O鈥橦agan DT, Mowat AM (1994) Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunology 81:661鈥?67PubMed Central PubMed
Mann JFS, Scales HE, Shakir E, Alexander J, Carter KC, Mullen AB, Ferro VA (2006) Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity. Methods 38:90鈥?5PubMed
Mann JF, Shakir E, Carter KC, Mullen AB, Alexander J, Ferro VA (2009) Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection. Vaccine 27:3643鈥?649PubMed
Mann JF, Stieh D, Klein K, de Stegmann DS, Cranage MP, Shattock RJ, McKay PF (2012) Transferrin conjugation confers mucosal molecular targeting to a model HIV-1 trimeric gp140 vaccine antigen. J Control Release 158:240鈥?49PubMed Central PubMed
Mansoor F, Earley B, Cassidy JP, Markey B, Foster C, Doherty S, Welsh MD (2014) Intranasal delivery of nanoparticles encapsulating BPI3V proteins induces an early humoral immune response in mice. Res Vet Sci 96:551鈥?57PubMed
Marasini N, Skwarczynski M, Toth I (2014) Oral delivery of nanoparticle-based vaccines. Expert Rev Vaccines 13:1361鈥?376PubMed
Marciani DJ (2003) Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today 8:934鈥?43PubMed
Marrack P, McKee AS, Munks MW (2009) Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 9:287鈥?93PubMed Central PubMed
Mason HS, Ball JM, Shi JJ, Jiang X, Estes MK, Arntzen CJ (1996) Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc Natl Acad Sci USA 93:5335鈥?340PubMed Central PubMed
Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC (2007) The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316:1628鈥?632PubMed
Mathew S, Lendlein A, Wischke C (2014) Characterization of protein-adjuvant coencapsulation in microparticles for vaccine delivery. Eur J Pharm Biopharm 87:403鈥?07PubMed
Matsuo K, Koizumi H, Akashi M, Nakagawa S, Fujita T, Yamamoto A, Okada N (2011) Intranasal immunization with poly(gamma-glutamic acid) nanoparticles entrapping antigenic proteins can induce potent tumor immunity. J Control Release 152:310鈥?16PubMed
McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR (1984) Human hepatitis B vaccine from recombinant yeast. Nature 307:178鈥?80PubMed
McCluskie MJ, Davis HL (1998) Cutting edge: CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol 161:4463鈥?466PubMed
McCluskie MJ, Weeratna RD, Krieg AM, Davis HL (2000) CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine 19:950鈥?57PubMed
McDermott MR, Heritage PL, Bartzoka V, Brook MA (1998) Polymer-grafted starch microparticles for oral and nasal immunization. Immunol Cell Biol 76:256鈥?62PubMed
Meng S, Liu Z, Xu L, Li L, Mei S, Bao L, Deng W, Li L, Lei R, Xie L et al (2011) Intranasal immunization with recombinant HA and mast cell activator C48/80 elicits protective immunity against 2009 pandemic H1N1 influenza in mice. PLoS One 6:e19863PubMed Central PubMed
Minato S, Iwanaga K, Kakemi M, Yamashita S, Oku N (2003) Application of polyethyleneglycol (PEG)-modified liposomes for oral vaccine: effect of lipid dose on systemic and mucosal immunity. J Control Release 89:189鈥?97PubMed
Mirchamsy H, Manhouri H, Hamedi M, Ahourai P, Fateh G, Hamzeloo Z (1996) Stimulating role of toxoids-laden liposomes in oral immunization against diphtheria and tetanus infections. Biologicals 24:343鈥?50PubMed
Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A (1984) Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 308:457鈥?60PubMed
Morris CB, Cheng E, Thanawastien A, Cardenas-Freytag L, Clements JD (2000) Effectiveness of intranasal immunization with HIV-gp160 and an HIV-1 env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT(R192G). Vaccine 18:1944鈥?951PubMed
Moschos SA, Bramwell VW, Somavarapu S, Alpar HO (2004) Adjuvant synergy: the effects of nasal coadministration of adjuvants. Immunol Cell Biol 82:628鈥?37PubMed
Mould JA, Drury JE, Frings SM, Kaupp UB, Pekosz A, Lamb RA, Pinto LH (2000) Permeation and activation of the M2 ion channel of influenza A virus. J Biol Chem 275:31038鈥?1050PubMed
Mowat AM, Smith RE, Donachie AM, Furrie E, Grdic D, Lycke N (1999) Oral vaccination with immune stimulating complexes. Immunol Lett 65:133鈥?40PubMed
Mummert ME (2005) Immunologic roles of hyaluronan. Immunol Res 31:189鈥?06PubMed
Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, Spyr C, Steffen R (2004) Use of the inactivated intranasal influenza vaccine and the risk of Bell鈥檚 palsy in Switzerland. N Engl J Med 350:896鈥?03PubMed
Muzzarelli RA (2010) Chitins and chitosans as immunoadjuvants and non-allergenic drug carriers. Mar Drugs 8:292鈥?12PubMed Central PubMed
Nagase S, Doyama R, Yagi K, Kondoh M (2013) Recent advances in claudin-targeting technology. Biol Pharm Bull 36:708鈥?14PubMed
Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W (1999) A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5:1157鈥?163PubMed
Neutra MR, Kozlowski PA (2006) Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6:148鈥?58PubMed
Neutra MR, Frey A, Kraehenbuhl JP (1996) Epithelial M cells: gateways for mucosal infection and immunization. Cell 86:345鈥?48PubMed
Niikura K, Matsunaga T, Suzuki T, Kobayashi S, Yamaguchi H, Orba Y, Kawaguchi A, Hasegawa H, Kajino K, Ninomiya T et al (2013) Gold nanoparticles as a vaccine platform: influence of size and shape on immunological responses in vitro and in vivo. ACS Nano 7:3926鈥?938PubMed
Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8:34鈥?7PubMed
Nochi T, Yuki Y, Takahashi H, Sawada S, Mejima M, Kohda T, Harada N, Kong IG, Sato A, Kataoka N et al (2010) Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat Mater 9:572鈥?78PubMed
Noh YW, Hong JH, Shim SM, Park HS, Bae HH, Ryu EK, Hwang JH, Lee CH, Cho SH, Sung MH et al (2013) Polymer nanomicelles for efficient mucus delivery and antigen-specific high mucosal immunity. Angew Chem Int Ed Engl 52:7684鈥?689PubMed
Oliveira CR, Rezende CM, Silva MR, Pego AP, Borges O, Goes AM (2012) A new strategy based on SmRho protein loaded chitosan nanoparticles as a candidate oral vaccine against schistosomiasis. PLoS Negl Trop Dis 6:e1894PubMed Central PubMed
Olszewska W, Steward MW (2001) Nasal delivery of epitope based vaccines. Adv Drug Deliv Rev 51:161鈥?71PubMed
Pandey RS, Dixit VK (2010) Evaluation of ISCOM vaccines for mucosal immunization against hepatitis B. J Drug Target 18:282鈥?91PubMed
Park CG (2014) Vaccine strategies utilizing C-type lectin receptors on dendritic cells in vivo. Clin Exp Vaccine Res 3:149鈥?54PubMed Central PubMed
Park YM, Lee SJ, Kim YS, Lee MH, Cha GS, Jung ID, Kang TH, Han HD (2013) Nanoparticle-based vaccine delivery for cancer immunotherapy. Immune Netw 13:177鈥?83PubMed Central PubMed
Pashine A, Valiante NM, Ulmer JB (2005) Targeting the innate immune response with improved vaccine adjuvants. Nat Med 11:S63鈥?8PubMed
Patel GB, Chen W (2010) Archaeal lipid mucosal vaccine adjuvant and delivery system. Expert Rev Vaccines 9:431鈥?40PubMed
Patel GB, Zhou HY, Ponce A, Chen WX (2007) Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines. Vaccine 25:8622鈥?636PubMed
Patel GB, Ponce A, Zhou H, Chen W (2008) Safety of intranasally administered archaeal lipid mucosal vaccine adjuvant and delivery (AMVAD) vaccine in mice. Int J Toxicol 27:329鈥?39PubMed
Pedersen GK, Ebensen T, Gjeraker IH, Svindland S, Bredholt G, Guzman CA, Cox RJ (2011) Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP. PLoS One 6:e26973PubMed Central PubMed
Petersson P, Hedenskog M, Alves D, Brytting M, Schroder U, Linde A, Lundkvist A (2010) The Eurocine (R) L3 adjuvants with subunit influenza antigens induce protective immunity in mice after intranasal vaccination. Vaccine 28:6491鈥?497PubMed
Pogrebnyak N, Golovkin M, Andrianov V, Spitsin S, Smirnov Y, Egolf R, Koprowski H (2005) Severe acute respiratory syndrome (SARS) S protein production in plants: development of recombinant vaccine. Proc Natl Acad Sci USA 102:9062鈥?067PubMed Central PubMed
Porporatto C, Bianco ID, Correa SG (2005) Local and systemic activity of the polysaccharide chitosan at lymphoid tissues after oral administration. J Leukoc Biol 78:62鈥?9PubMed
Prevec L, Schneider M, Rosenthal KL, Belbeck LW, Derbyshire JB, Graham FL (1989) Use of human adenovirus-based vectors for antigen expression in animals. J Gen Virol 70:429鈥?34PubMed
Pun PB, Bhat AA, Mohan T, Kulkarni S, Paranjape R, Rao DN (2009) Intranasal administration of peptide antigens of HIV with mucosal adjuvant CpG ODN coentrapped in microparticles enhances the mucosal and systemic immune responses. Int Immunopharmacol 9:468鈥?77PubMed
Qian ZM, Li H, Sun H, Ho K (2002) Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 54:561鈥?87PubMed
Rappuoli R, Aderem A (2011) A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 473:463鈥?69PubMed
Rebelatto MC, Guimond P, Bowersock TL, HogenEsch H (2001) Induction of systemic and mucosal immune response in cattle by intranasal administration of pig serum albumin in alginate microparticles. Vet Immunol Immunopathol 83:93鈥?05PubMed
Reed SG, Bertholet S, Coler RN, Friede M (2009) New horizons in adjuvants for vaccine development. Trends Immunol 30:23鈥?2PubMed
Reineke JJ, Cho DY, Dingle YT, Morello AP 3rd, Jacob J, Thanos CG, Mathiowitz E (2013) Unique insights into the intestinal absorption, transit, and subsequent biodistribution of polymer-derived microspheres. Proc Natl Acad Sci USA 110:13803鈥?3808PubMed Central PubMed
Renegar KB, Small PA Jr, Boykins LG, Wright PF (2004) Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 173:1978鈥?986PubMed
Rivera-Hernandez T, Hartas J, Wu Y, Chuan YP, Lua LH, Good M, Batzloff MR, Middelberg AP (2013) Self-adjuvanting modular virus-like particles for mucosal vaccination against group A streptococcus (GAS). Vaccine 31:1950鈥?955PubMed
Rose MA, Zielen S, Baumann U (2012) Mucosal immunity and nasal influenza vaccination. Expert Rev Vaccines 11:595鈥?07PubMed
Rydell N, Sjoholm I (2004) Oral vaccination against diphtheria using polyacryl starch microparticles as adjuvant. Vaccine 22:1265鈥?274PubMed
Rydell N, Sjoholm I (2005) Mucosal vaccination against diphtheria using starch microparticles as adjuvant for cross-reacting material (CRM197) of diphtheria toxin. Vaccine 23:2775鈥?783PubMed
Rydell N, Stertman L, Sjoholm I (2005) Starch microparticles as vaccine adjuvant. Expert Opin Drug Deliv 2:807鈥?28PubMed
Sahdev P, Ochyl LJ, Moon JJ (2014) Biomaterials for nanoparticle vaccine delivery systems. Pharm Res 31:2563鈥?582PubMed
Sajadi Tabassi SA, Tafaghodi M, Jaafari MR (2008) Induction of high antitoxin titers against tetanus toxoid in rabbits by intranasal immunization with dextran microspheres. Int J Pharm 360:12鈥?7PubMed
Sanchez MV, Ebensen T, Schulze K, Cargnelutti D, Blazejewska P, Scodeller EA, Guzman CA (2014) Intranasal delivery of influenza rNP adjuvanted with c-di-AMP induces strong humoral and cellular immune responses and provides protection against virus challenge. PLoS One 9:e104824PubMed Central PubMed
Sanders MT, Brown LE, Deliyannis G, Pearse MJ (2005) ISCOM-based vaccines: the second decade. Immunol Cell Biol 83:119鈥?28PubMed
Santi L, Batchelor L, Huang Z, Hjelm B, Kilbourne J, Arntzen CJ, Chen Q, Mason HS (2008) An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles. Vaccine 26:1846鈥?854PubMed Central PubMed
Saraf S, Mishra D, Asthana A, Jain R, Singh S, Jain NK (2006) Lipid microparticles for mucosal immunization against hepatitis B. Vaccine 24:45鈥?6PubMed
Sarti F, Perera G, Hintzen F, Kotti K, Karageorgiou V, Kammona O, Kiparissides C, Bernkop-Schnurch A (2011) In vivo evidence of oral vaccination with PLGA nanoparticles containing the immunostimulant monophosphoryl lipid A. Biomaterials 32:4052鈥?057PubMed
Sayin B, Somavarapu S, Li XW, Sesardic D, Senel S, Alpar OH (2009) TMC-MCC (N-trimethyl chitosan-mono-N-carboxymethyl chitosan) nanocomplexes for mucosal delivery of vaccines. Eur J Pharm Sci 38:362鈥?69PubMed
Scheerlinck JP, Greenwood DL (2008) Virus-sized vaccine delivery systems. Drug Discov Today 13:882鈥?87PubMed
Scolnick EM, McLean AA, West DJ, McAleer WJ, Miller WJ, Buynak EB (1984) Clinical evaluation in healthy adults of a hepatitis B vaccine made by recombinant DNA. JAMA 251:2812鈥?815PubMed
Seder RA, Hill AV (2000) Vaccines against intracellular infections requiring cellular immunity. Nature 406:793鈥?98PubMed
Senchi K, Matsunaga S, Hasegawa H, Kimura H, Ryo A (2013) Development of oligomannose-coated liposome-based nasal vaccine against human parainfluenza virus type 3. Front Microbiol 4:346PubMed Central PubMed
Shank-Retzlaff M, Wang F, Morley T, Anderson C, Hamm M, Brown M, Rowland K, Pancari G, Zorman J, Lowe R et al (2005) Correlation between mouse potency and in vitro relative potency for human papillomavirus Type 16 virus-like particles and gardasil (R) vaccine samples. Hum Vaccines 1:191鈥?97
Sharma S, Mukkur TK, Benson HA, Chen Y (2009) Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. J Pharm Sci 98:812鈥?43PubMed
Shaw N, Ouyang SY, Liu ZJ (2013) Binding of bacterial secondary messenger molecule c di-GMP is a STING operation. Protein Cell 4:117鈥?29PubMed
Sheppard NC, Brinckmann SA, Gartlan KH, Puthia M, Svanborg C, Krashias G, Eisenbarth SC, Flavell RA, Sattentau QJ, Wegmann F (2014) Polyethyleneimine is a potent systemic adjuvant for glycoprotein antigens. Int Immunol 26:531鈥?38PubMed
Shibata Y, Honda I, Justice JP, Van Scott MR, Nakamura RM, Myrvik QN (2001) Th1 adjuvant N-acetyl-d -glucosamine polymer up-regulates Th1 immunity but down-regulates Th2 immunity against a mycobacterial protein (MPB-59) in interleukin-10-knockout and wild-type mice. Infect Immun 69:6123鈥?130PubMed Central PubMed
Shukla A, Khatri K, Gupta PN, Goyal AK, Mehta A, Vyas SP (2008) Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes). J Pharm Pharm Sci 11:58鈥?6
Shukla A, Katare OP, Singh B, Vyas SP (2010) M-cell targeted delivery of recombinant hepatitis B surface antigen using cholera toxin B subunit conjugated bilosomes. Int J Pharm 385:47鈥?2PubMed
Shukla A, Singh B, Katare OP (2011) Significant systemic and mucosal immune response induced on oral delivery of diphtheria toxoid using nano-bilosomes. Br J Pharmacol 164:820鈥?27PubMed Central PubMed
Singh M, O鈥橦agan D (1998) The preparation and characterization of polymeric antigen delivery systems for oral administration. Adv Drug Deliv Rev 34:285鈥?04PubMed
Singh M, Briones M, O鈥橦agan DT (2001) A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. J Control Release 70:267鈥?76PubMed
Singh J, Pandit S, Bramwell VW, Alpar HO (2006) Diphtheria toxoid loaded poly-(epsilon-caprolactone) nanoparticles as mucosal vaccine delivery systems. Methods 38:96鈥?05PubMed
Skene CD, Sutton P (2006) Saponin-adjuvanted particulate vaccines for clinical use. Methods 40:53鈥?9PubMed
Skountzou I, Quan FS, Gangadhara S, Ye L, Vzorov A, Selvaraj P, Jacob J, Compans RW, Kang SM (2007) Incorporation of glycosylphosphatidylinositol-anchored granulocyte- macrophage colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles. J Virol 81:1083鈥?094PubMed Central PubMed
Smith DM, Simon JK, Baker JR Jr (2013) Applications of nanotechnology for immunology. Nat Rev Immunol 13:592鈥?05PubMed
Sneh-Edri H, Likhtenshtein D, Stepensky D (2011) Intracellular targeting of PLGA nanoparticles encapsulating antigenic peptide to the endoplasmic reticulum of dendritic cells and its effect on antigen cross-presentation in vitro. Mol Pharm 8:1266鈥?275PubMed
Somavarapu S, Pandit S, Gradassi G, Bandera M, Ravichandran E, Alpar OH (2005) Effect of vitamin E TPGS on immune response to nasally delivered diphtheria toxoid loaded poly(caprolactone) microparticles. Int J Pharm 298:344鈥?47PubMed
Specht EA, Mayfield SP (2014) Algae-based oral recombinant vaccines. Front Microbiol 5:60PubMed Central PubMed
Staats HF, Fielhauer JR, Thompson AL, Tripp AA, Sobel AE, Maddaloni M, Abraham SN, Pascual DW (2011) Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits. PLoS One 6:e16532PubMed Central PubMed
Stephenson I, Zambon MC, Rudin A, Colegate A, Podda A, Bugarini R, Del Giudice G, Minutello A, Bonnington S, Holmgren J et al (2006) Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol 80:4962鈥?970PubMed Central PubMed
Sui ZW, Chen QJ, Fang F, Zheng M, Chen Z (2010) Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant. Vaccine 28:7690鈥?698PubMed
Sun HX, Xie Y, Ye YP (2009a) Advances in saponin-based adjuvants. Vaccine 27:1787鈥?796PubMed
Sun HX, Xie Y, Ye YP (2009b) ISCOMs and ISCOMATRIX. Vaccine 27:4388鈥?401PubMed
Svindland SC, Pedersen GK, Pathirana RD, Bredholt G, Nostbakken JK, Jul-Larsen A, Guzman CA, Montomoli E, Lapini G, Piccirella S et al (2013) A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine. Influenza Other Respir Viruses 7:1181鈥?193PubMed
Tafaghodi M, Rastegar S (2010) Preparation and in vivo study of dry powder microspheres for nasal immunization. J Drug Target 18:235鈥?42PubMed
Takahashi H (2003) Antigen presentation in vaccine development. Comp Immunol Microbiol Infect Dis 26:309鈥?28PubMed
Tam JP (1988) Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci USA 85:5409鈥?413PubMed Central PubMed
Tamura S, Kurata T (2004) Defense mechanisms against influenza virus infection in the respiratory tract mucosa. Jpn J Infect Dis 57:236鈥?47PubMed
Tao W, Ziemer KS, Gill HS (2014) Gold nanoparticle-M2e conjugate coformulated with CpG induces protective immunity against influenza A virus. Nanomedicine (Lond) 9:237鈥?51
Thomas C, Gupta V, Ahsan F (2009) Influence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses. Int J Pharm 379:41鈥?0PubMed
Tiwari S, Agrawal GP, Vyas SP (2010) Molecular basis of the mucosal immune system: from fundamental concepts to advances in liposome-based vaccines. Nanomedicine (Lond) 5:1617鈥?640
Tiwari B, Agarwal A, Kharya AK, Lariya N, Saraogi G, Agrawal H, Agrawal GP (2011a) Immunoglobulin immobilized liposomal constructs for transmucosal vaccination through nasal route. J Liposome Res 21:181鈥?93PubMed
Tiwari S, Verma SK, Agrawal GP, Vyas SP (2011b) Viral protein complexed liposomes for intranasal delivery of hepatitis B surface antigen. Int J Pharm 413:211鈥?19PubMed
Tobio M, Gref R, Sanchez A, Langer R, Alonso MJ (1998) Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm Res 15:270鈥?75PubMed
Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145鈥?60PubMed
Trinchieri G (1995) Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 13:251鈥?76PubMed
Tripathi V, Chitralekha KT, Bakshi AR, Tomar D, Deshmukh RA, Baig MA, Rao DN (2006) Inducing systemic and mucosal immune responses to B-T construct of F1 antigen of Yersinia pestis in microsphere delivery. Vaccine 24:3279鈥?289PubMed
Trumpfheller C, Caskey M, Nchinda G, Longhi MP, Mizenina O, Huang Y, Schlesinger SJ, Colonna M, Steinman RM (2008) The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci USA 105:2574鈥?579PubMed Central PubMed
Turner TM, Jones LP, Tompkins SM, Tripp RA (2013) A novel influenza virus hemagglutinin-respiratory syncytial virus (RSV) fusion protein subunit vaccine against influenza and RSV. J Virol 87:10792鈥?0804PubMed Central PubMed
Ulery BD, Kumar D, Ramer-Tait AE, Metzger DW, Wannemuehler MJ, Narasimhan B (2011) Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases. PLoS One 6:e17642PubMed Central PubMed
van der Lubben IM, Verhoef JC, Borchard G, Junginger HE (2001) Chitosan for mucosal vaccination. Adv Drug Deliv Rev 52:139鈥?44PubMed
van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR (2000) Cutting edge: The mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 165:4778鈥?782PubMed
van Riet E, Ainai A, Suzuki T, Kersten G, Hasegawa H (2014) Combatting infectious diseases; nanotechnology as a platform for rational vaccine design. Adv Drug Deliv Rev 74:28鈥?4PubMed
Velasquez LS, Shira S, Berta AN, Kilbourne J, Medi BM, Tizard I, Ni Y, Arntzen CJ, Herbst-Kralovetz MM (2011) Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine. Vaccine 29:5221鈥?231PubMed Central PubMed
Vicente S, Peleteiro M, Diaz-Freitas B, Sanchez A, Gonzalez-Fernandez A, Alonso MJ (2013) Co-delivery of viral proteins and a TLR7 agonist from polysaccharide nanocapsules: a needle-free vaccination strategy. J Control Release 172:773鈥?81PubMed
Vila A, Sanchez A, Evora C, Soriano I, Vila Jato JL, Alonso MJ (2004) PEG-PLA nanoparticles as carriers for nasal vaccine delivery. J Aerosol Med 17:174鈥?85PubMed
Vila A, Sanchez A, Evora C, Soriano I, McCallion O, Alonso MJ (2005) PLA-PEG particles as nasal protein carriers: the influence of the particle size. Int J Pharm 292:43鈥?2PubMed
Wang X, Meng D (2014) Innate endogenous adjuvants prime to desirable immune responses via mucosal routes, Protein Cell, 1鈥?5
Wang L, Cheng C, Ko SY, Kong WP, Kanekiyo M, Einfeld D, Schwartz RM, King CR, Gall JG, Nabel GJ (2009) Delivery of human immunodeficiency virus vaccine vectors to the intestine induces enhanced mucosal cellular immunity. J Virol 83:7166鈥?175PubMed Central PubMed
Wegmann F, Gartlan KH, Harandi AM, Brinckmann SA, Coccia M, Hillson WR, Kok WL, Cole S, Ho LP, Lambe T et al (2012) Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens. Nat Biotechnol 30:883鈥?88PubMed Central PubMed
Wikingsson LD, Sjoholm I (2002) Polyacryl starch microparticles as adjuvant in oral immunisation, inducing mucosal and systemic immune responses in mice. Vaccine 20:3355鈥?363PubMed
Williamson ED, Oyston PC (2013) Protecting against plague: towards a next-generation vaccine. Clin Exp Immunol 172:1鈥?PubMed Central PubMed
Wong SK, Li W, Moore MJ, Choe H, Farzan M (2004) A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem 279:3197鈥?201PubMed
Wu T, Li SW, Zhang J, Ng MH, Xia NS, Zhao Q (2012) Hepatitis E vaccine development: a 14 year odyssey. Hum Vaccin Immunother 8:823鈥?27PubMed
Yoo MK, Kang SK, Choi JH, Park IK, Na HS, Lee HC, Kim EB, Lee NK, Nah JW, Choi YJ et al (2010) Targeted delivery of chitosan nanoparticles to Peyer鈥檚 patch using M cell-homing peptide selected by phage display technique. Biomaterials 31:7738鈥?747PubMed
Yoshikawa T, Suzuki Y, Nomoto A, Sata T, Kurata T, Tamura S (2002) Antibody responses and protection against influenza virus infection in different congenic strains of mice immunized intranasally with adjuvant-combined A/Beijing/262/95 (H1N1) virus hemagglutinin or neuraminidase. Vaccine 21:60鈥?6PubMed
Zhang P, Yang QB, Marciani DJ, Martin M, Clements JD, Michalek SM, Katz J (2003) Effectiveness of the quillaja saponin semi-synthetic analog GPI-0100 in potentiating mucosal and systemic responses to recombinant HagB from Porphyromonas gingivalis. Vaccine 21:4459鈥?471PubMed
Zhang N, Jiang S, Du L (2014) Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev Vaccines 13:761鈥?74PubMed Central PubMed
Zhao Q, Li S, Yu H, Xia N, Modis Y (2013) Virus-like particle-based human vaccines: quality assessment based on structural and functional properties. Trends Biotechnol 31:654鈥?63PubMed
Zhao L, Seth A, Wibowo N, Zhao CX, Mitter N, Yu C, Middelberg AP (2014) Nanoparticle vaccines. Vaccine 32:327鈥?37PubMed
Zhu Q, Talton J, Zhang G, Cunningham T, Wang Z, Waters RC, Kirk J, Eppler B, Klinman DM, Sui Y et al (2012) Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection. Nat Med 18:1291鈥?296PubMed - 作者单位：Shujing Wang (1)
Huiqin Liu (1)
Xinyi Zhang (1)
Feng Qian (1)
1. Department of Pharmacology and Pharmaceutical Sciences, School of Medicine and Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Tsinghua University, Beijing, 100084, China - 刊物主题：Biochemistry, general; Protein Science; Cell Biology; Stem Cells; Human Genetics; Developmental Biology;
- 出版者：Springer Berlin Heidelberg
- ISSN：1674-8018
文摘